Table 2.
Mammary carcinomas
| Case
|
Age (days)
|
Tumor phenotype
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Size (mm)
|
Pattern
|
Borders
|
Nuclear grade
|
Immunohistochemistry
|
|||||||
| ER
|
PR
|
neu
|
cD1
|
p21
|
p53
|
||||||
| A. Brcaltr/tr | |||||||||||
| 1 | 280 | 13 | Solid with few microglandular elements and focal adenoacanthoma | Invasive | Int./high | − | − | − | + | + | + |
| 2 | 334 | 14 | Peripherally solid and centrally cystic with stromal desmoplasia | Highly invasive | High | − | − | − | + | + | + |
| 3 | 354 | 12 | Papillary, cribriform, and cystic | Pushing margins | Int./high | + | + | − | + | + | + |
| 4 | 422 | 1 | Adenoacanthoma | Pushing margins | Low | ± | − | ± | + | + | − |
| 5 | 440 | 8 | Infiltrating lobular pattern (male animal) | Highly invasive | Low | − | − | + | ± | + | |
| 6 | 447 | 7 | Papillary | Highly invasive | High | ± | − | + | + | + | + |
| 7a | 474 | 12 | Ductal carcinoma: Dunn type B pattern (tubular, alveolar, papillary, and large cell [“myc-like” elements) in combination with Dunn type A pattern (focal acinar growth); also multifocal DCIS at tumor borders | Invasive | Int./high | ± | + | + | + | ± | ± |
| 7b | DCIS emerging from a background of HAN | ||||||||||
| 8 | 494 | 8 | Predominantly cystic in combination with solid (“neu-like”), glandular, and focally mucinous patterns | Invasive | Intermediate | ± | + | − | + | + | + |
| 9 | 525 | <0.5 | DCIS | ||||||||
| 10 | 589 | 17 | Poorly differentiated adenocarcinoma with extensive sarcomatous metaplasia | Highly invasive | High | − | − | − | + | +++ | |
| 11 | 654 | <0.5 | DCIS | ||||||||
| 12 | 680 | 2 | Ductal tubular | Invasive | Intermediate | − | − | − | + | + | + |
| B. Brcaltr/tr/p53+/− | |||||||||||
| 13 | 179 | 16 | Solid and glandular | Invasive | Very high | − | − | − | + | ± | ± |
| 14 | 386 | 10 | Solid and focally cystic with focal adenoacanthoma | Invasive | High | ||||||
Tumors in different mammary glands are described in case 7a and b. Immunostaining is indicated as positive (+), strongly positive (+++), weakly positive (±), or negative (−). When an immunophenotype was not determined, the space is left blank.
(ER) estrogen receptor; (PR) progesterone receptor; (cD1) cyclin D1; (int.) intermediate; (DCIS) ductal carcinoma in situ; (HAN) hyperplastic alveolar nodule.